Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

d; "We are very pleased to enter this partnership with ThromboGenics and BioInvent. This novel antibody, TB-403 has the potential to play a major role in the treatment of cancer and we are committed to driving ahead with its development. In addition, we look forward to developing a strong working relationship with ThromboGenics and BioInvent."

Notes to Editors:

About TB-403

TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB) at the University of Leuven, Belgium, where the therapeutic potential of anti-PlGF agents to treat cancer was first developed in the laboratory of Prof. Peter Carmeliet.

Angiogenesis inhibitors such as TB-403 are therapeutic agents that work by blocking the development of new blood vessels, thereby depriving growing cancer tumour cells of oxygen and nutrients. This approach in turn is thought to stop the tumour from growing and spreading to other parts of the body. PlGF is a homologue of VEGF and current preclinical evidence suggests that it may not affect normal, physiological angiogenesis and is predominantly involved in angiogenesis of malignant tissue.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF). ThromboGenics and BioInvent have recently signed a license agreement with Roche for TB-403 worth EUR 500 million plus royalties. TB-403 is scheduled to enter a Phase Ib clinical t
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 ... Company specializing in cannabis formulation-based drug development and ... New York Times for taking a strong position ... in its Sunday, July 27, 2014 publication.  The ... upcoming editorials and articles this week exploring the ...
(Date:7/29/2014)... HILLS, Calif. , July 29, 2014 /PRNewswire/ ... specializing in personalized medicine, treatment of infectious diseases ... strategies of prognosis and prevention of pathologies like ... of August 1, 2014, ImmunoClin Corporation will complete ... Washington, D.C. , a key ...
(Date:7/29/2014)... 29, 2014 TransVac Solutions, the trusted ... and transport solutions for hospitals, will be exhibiting at ... (ASHE) Annual Conference & Technical Exhibition Aug. 3-6 in ... technology for making hospitals cleaner, reducing infection risk and ... hospital’s life cycle. Staff will be available at ...
(Date:7/29/2014)... July 29, 2014 July 29, ... pioneer in the biotechnology industry, announced that it ... Securities, Inc. to explore financing opportunities that build ... a breakthrough vaccine platform with the potential to ... company exclusively licensed the well-established LAMP platform from ...
Breaking Biology Technology:Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3
... Inc.,(Nasdaq: ENMD ) a clinical-stage pharmaceutical company ... diseases,announced today that James S. Burns, President and ... the ThinkEquity Partners, 5th Annual,Growth Conference, to be ... Francisco,California, September 17-20, 2007. Mr. Burns, presentation is ...
... Sept. 13 VaxGen,Inc. (Pink Sheets: VXGN) today ... to align its cost structure with,its pursuit of ... VaxGen is reducing its workforce from 61 to ... monthly cash expenditures used in operating,activities to $1.4 ...
... COLUMBIA, Md., Sept. 13 Martek Biosciences,Corporation (Nasdaq: ... presenting at the,upcoming UBS Global Life Sciences Conference ... September 24-27, 2007 at the Grand Hyatt in ... on Tuesday, September 25th at,3:00 p.m. Eastern Time. ...
Cached Biology Technology:EntreMed to Present at ThinkEquity Partners' 5th Annual Growth Conference 2VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives 2
(Date:7/29/2014)... YORK , July 29, 2014  When it comes to ... new devices, if not the last. However, when it comes to ... Though the market for the Internet of Things and its ... make an impact in the healthcare industry, whether it,s in the ... to keep us fit. With that in mind, InformationWeek ...
(Date:7/29/2014)... an easier method to create DNAprotein conjugates. The ... diagnosing diseases. , DNA linked to proteins ... can be used in diagnostic techniques, nanotechnology and ... with DNA can be used for purposes ... biological material. The method also provides easier access ...
(Date:7/29/2014)... (UM SOD) and Medicine (UM SOM) jointly announced ... million grant award from the National Institute of ... Institutes of Health to study the causes, prevention ... which renews a previous $12 million five-year NIAID-funded ... research by studying chlamydial and gonorrheal diseases as ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4
... work in protein production, a Princeton-led team has discovered ... doing so, they also have discovered how one protein ... cancer-fighting process. In a study appearing in the ... Thomas Silhavy, Princeton,s Warner-Lambert Parke-Davis Professor of Molecular Biology, ...
... Virginia Tech has shown that the oldest complex life ... million years ago likely fed by osmosis. ... the fern-shaped rangeomorphs and the air mattress-shaped erniettomorphs. These ... through their outer membrane, much like modern microscopic bacteria, ...
... under the summer heat, consider this: your child may ... cool old days." To illustrate expected increases in extreme ... projections made with global climate models. Scientific literature ... hot days, "heat waves" (very high temperatures sustained over several ...
Cached Biology News:Princeton team learns why some drugs pack such a punch 2Princeton team learns why some drugs pack such a punch 3Geobiologists propose that the earliest complex organisms fed by absorbing ocean buffet 2Geobiologists propose that the earliest complex organisms fed by absorbing ocean buffet 3Those dog days of August: 3 times the heat by 2050? 2
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
... rapid and efficient removal of short primers, ... from PCR products (Figure 1). The simple ... Buffer options for fragments >100 bp or ... either single column or 96-well plate format ...
... capped transcripts with the translation boosting Cap ... 100% capped (versus 40% to 80% capped ... about 2 hours. mScript™ also features the ... to be up to 50% more efficient ...
... Baculovirus Expression System with Gateway™ Technology ... plasmids containing the polyhedrin promoter. The ... baculovirus genome (bacmid DNA) by site-specific ... cells. The recombinant bacmid DNA is ...
Biology Products: